Skip to main content

Table 2 Frequency of rescue medication and Cost-Effectiveness Ratio

From: Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

 

Rescue medication

Vomiting

Nausea

Cost of prophylaxis regimen (JPY)

Costs of the antiemetics (JPY)

CR (Overall)

CER (JPY/CR)

Frequency (n)

Mean cost (SD)

Amount total (JPY)

Sensitivity analysis

Pts. No. (%)

Frequency

Median (range)

Mode

GRA (1 mg)

total (n = 413)

717 (n = 153)

178.9 (712.7)

73,883.8

71,106.4 - 79,017.1

75 (18.2%)

1092

1 (0–15)

0

15,342.8

15,521.7

0.591

26,263.4

category 1 (n = 244)

0

0

0

–

0

199

0 (0–10)

0

category 2 (n = 135)

468 (n = 122)

382.7 (1078)

51,663.5

49,709.9 - 54,279.8

52 (38.5%)

631

5 (0–15)

5

category 3 (n = 34)

249 (n = 31)

635.5 (991.9)

22,220.3

21,396.5 - 24,737.3

23 (67.6%)

262

8 (0–15)

5

PALO (0.75 mg)

total (n = 414)

573 (n = 123)

143.2 (795.8)

59,292.7

57,707.5 - 60,972.8

65 (15.7%)

887

1 (0–13)

0

27,863.8

28,007

0.657

42,628.6

category 1 (n = 272)

0

0

0

–

0

195

0 (0–7)

0

category 2 (n = 108)

356 (n = 92)

286.5 (1003.3)

30,942.6

30,007.6 - 32,242.3

44 (40.7%)

485

4 (0–13)

3

category 3 (n = 34)

217 (n = 31)

833.8 (1983.3)

28,350.1

27,699.9 - 28,730.5

21 (61.8%)

207

6.5 (0–13)

7

  1. With regard to a case of CR or non-CR, we set three categories according to the development of CINV in overall, acute and delayed phase (i.e. category 1: CR (0–120 h), category 2: non-CR delayed, category 3: non-CR acute) and then investigated retrospectively the direct medical costs of antiemetics, the number of patients with vomiting, and the number of nausea episodes during observation periods
  2. range = minimum to maximum
  3. CR: Complete Response (no vomiting/retching and no rescue medication)
  4. CER: Cost-Effectiveness Ratio